Zynerba Pharmaceuticals, is a company I see value in. From a technical analysis standpoint, the positive uptrend is an attractive characteristic. Also, with the recent pullback, if ZYNE continues to be supported by the exponential moving average (EMA), it is currently at a “good buy” area. Click the title of the post to read more.
Month: May 2019
Non-Pharm Finance: Part I
Profit while Simulation Trading
Clinuvel Pharmaceuticals Limited (CLVLY)
Clinuvel is currently carries high volatility, the positive uptrend is appealing for short-term swing trades. Clinuvel is currently near its previous resistance. From a technical analysis, I don’t believe it is currently in the “good buy” territory. However, if Clinuvel continues to make “higher highs and higher lows,” that break the resistance, Clinuvel might offer a substantial profit. Click the title of the post to read more.
Update to Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) – Approved
Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO®
Update to Heron Therapeutics, Inc. (Nasdaq: HRTX)
Heron Therapeutics Receives Complete Response Letter For HTX-011 For The Management Of Postoperative Pain Heron received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) on April 30, 2019.¹ A CRL is sent to drug manufacturers to indicate that the review cycle for an application is complete and that the application … Continue reading Update to Heron Therapeutics, Inc. (Nasdaq: HRTX)